Colloid Fluids Should Not Be Used for Hemorrhagic Shock Resuscitation
Colloid solutions are not recommended for initial resuscitation in hemorrhagic shock because they provide no mortality benefit over crystalloids while significantly increasing the risks of renal failure, coagulopathy, and bleeding complications. 1
Key Evidence Against Colloids
The 2022 French guidelines for critically ill patients provide a GRADE 2- recommendation (strong agreement) against using colloid solutions compared to non-hypertonic crystalloids in hemorrhagic shock, specifically to reduce mortality and renal replacement therapy requirements 1.
Why Colloids Fail Despite Better Volume Expansion
While colloids have superior volume expansion capacity compared to crystalloids (ratio of approximately 1.5:1), this theoretical advantage does not translate into improved clinical outcomes 1. The evidence demonstrates:
No mortality benefit: Recent meta-analyses of trauma patients showed no reduction in mortality with hydroxyethyl starches or gelatins versus crystalloids 1
Increased renal failure risk: The FLASH study found significantly more renal failure in the hydroxyethyl starch group (OR 1.34, p = 0.05) 1
Coagulopathy and increased bleeding: Hydroxyethyl starch administration during major surgery was associated with hemostasis disorders and significantly higher hemorrhagic risk compared to crystalloids 1
Higher transfusion requirements: ICU patients receiving colloids required more blood transfusions 1
Specific Colloid Concerns
Hydroxyethyl Starches (HES):
- Restricted by French health authorities since 2014 to second-line use only when crystalloids are insufficient 1
- Associated with coagulation dysfunction that worsens ongoing hemorrhage
- Increased risk of acute kidney injury requiring dialysis
Gelatins:
- No demonstrated mortality benefit over crystalloids in trauma patients 1
- Similar concerns regarding coagulation effects
Albumin:
- No specific studies support its use in hemorrhagic shock 1
- Subgroup analysis from the SAFE study (trauma patients without TBI) showed no benefit 1
- Significantly more expensive than crystalloids without proven advantage
- Not recommended for hemorrhagic shock resuscitation 1
The Crystalloid Alternative
Balanced crystalloids (Ringer's Lactate or Plasmalyte) should be used as first-line therapy rather than 0.9% NaCl, with a GRADE 2+ recommendation 1. This is particularly important because hemorrhagic shock often requires massive volumes (5,000-10,000 mL in the first 24 hours for trauma), and high-volume chloride-rich solutions are associated with:
- Worse acid-base balance
- Potentially increased mortality
- Higher risk of hyperchloremic metabolic acidosis
Clinical Bottom Line
The algorithm is straightforward:
- Initial resuscitation: Balanced crystalloids (Ringer's Lactate or Plasmalyte)
- If crystalloids insufficient: Continue crystalloids with blood products and hemostatic resuscitation—NOT colloids
- Avoid colloids entirely in the hemorrhagic shock setting due to harm without benefit
Common Pitfall to Avoid
Do not be tempted to use colloids based on their superior intravascular retention properties. The physiologic advantage of colloids is completely negated by their adverse effects on coagulation and renal function in the bleeding patient 1. The patient actively hemorrhaging needs hemostatic competence more than volume expansion efficiency—colloids undermine this critical need.
The 2023 European trauma guidelines 2 acknowledge that while colloids can restore intravascular volume more effectively, they impair coagulation and platelet function, making them inappropriate for hemorrhagic shock where maintaining hemostatic capacity is paramount.